
· Executive Brief
Myasthenia Gravis Awareness Month 2026
A practical executive framework for access, ownership, handoffs, measurement, and improvement.

Leadership signal
Myasthenia Gravis Awareness Month can serve as an executive operating checkpoint.
Awareness can generate questions and requests for help. Executive teams can prepare by clarifying the first point of contact, the qualified team that accepts the request, the handoff standard, and the method used to verify completion without assuming that one route fits every person.
Start by distinguishing what is known from what the organization still needs to learn. A campaign plan, communication volume, or meeting count does not establish that a route is usable. Leaders need direct listening, clear ownership, locally defined measures, and a method for keeping exceptions visible.
Executive opening
Myasthenia gravis is a rare disease with common operating failures
Myasthenia gravis is rare, but the operating challenges it creates are familiar to every health system. Symptoms such as drooping eyelids, double vision, swallowing difficulty or limb weakness can fluctuate. Patients may be seen in eye clinics, primary care, emergency departments or gastroenterology before anyone considers a neuromuscular cause. When the condition worsens, it can move quickly from an outpatient concern to a respiratory emergency. Each of those settings belongs to a different service line, so no single leader sees the full journey unless the organization deliberately connects the data.
Delay is common. In a Brazilian public tertiary center, the median diagnostic delay among 150 adults was 11 months, and 47.3% waited a year or more.[1] In that cohort, documented myasthenic crisis occurred in 25.2% of patients with available records.[1] The authors called for earlier recognition, specialized management and improved access to comprehensive care.[1]
The financial stakes are also high. In a large U.S. database study, adults with generalized myasthenia gravis had mean incremental healthcare costs of $4,155 per month compared with matched adults without the disease.[15] Inpatient costs drove most of that difference, and costs were more than three times higher among patients with an exacerbation or crisis.[15]
Myasthenia Gravis Awareness Month is a useful moment for leaders to ask where those delays and crises originate and who owns each step. The sections below summarize peer-reviewed evidence on diagnosis, crisis care, infusion and specialty therapies, remote monitoring, equity and the patient experience. They are intended to sit alongside the executive guidance already on this page, giving operating leaders and boards a shared factual base for deciding where to act first. The focus is on operations, including access, handoffs, workforce, equity and measurement, rather than individual treatment choices.
Current evidence
What the research says about delay, misdiagnosis and burden
Diagnosis is difficult in both directions. A specialized clinic reviewed 561 patients referred with suspected myasthenia gravis and ruled out the diagnosis in 167.[2] An alternative diagnosis was reached in 53.9% of that mimic group.[2] Among mimic patients, 7.9% had a previous positive antibody result later confirmed as a false positive, and up to 23% had received immunosuppressants during the diagnostic process.[2] It took a mean of more than two years to rule out the disease in seronegative cases.[2]
Related conditions show how the absence of obvious findings can slow diagnosis. One study compared 12 patients with Lambert-Eaton myasthenic syndrome and 20 with antibody-positive generalized myasthenia gravis.[3] The median interval from symptom onset to diagnosis was 7.5 months compared with 1.5 months.[3] In the Lambert-Eaton group, 58% had normal strength on manual muscle testing despite reporting fatigue.[3] Diagnostic delay was associated with that absence of objective weakness.[3]
Patients without detectable antibodies carry an added burden. In a questionnaire survey, 237 patients with seronegative disease were younger at onset and had longer diagnostic delays than antibody-positive patients.[13] Complete stable remission was less frequent, at 15.9% compared with 27.8%.[13] Employment restrictions were more common, affecting 64.4% compared with 49.3%.[13] The authors linked the higher burden to diagnostic delay, worse treatment response and sociodemographic factors.[13]
The disease also weighs heavily on daily life beyond symptoms. Interviews and a survey of 239 patients and 81 caregivers in the United States identified 25 impact elements across eight life domains.[6] Patients rated occupational impact and planning and autonomy highest, each with a mean score of 4.0 on a five-point scale.[6] Caregivers rated financial impact highest, with a mean of 3.7.[6] Numerically higher impact scores were observed among patients with more severe disease and younger patients.[6]
Taken together, the evidence suggests that the costliest failures are not rare events. They are delayed referrals, uncertain diagnoses and missed signs of worsening that each health system can measure.[1][2][15] Most organizations already hold the data needed to see them: referral dates, test orders, admissions and infusion records. The executive task is to assemble those records into a view of the whole pathway rather than separate departmental reports.
Figure 1
Where myasthenia gravis pathways carry the heaviest load
Percent of patients in each study experiencing the reported pathway outcome. Values are copied from the cited studies [1], [9], [11], [13], [14]; none is estimated.
Data note. These values come from different countries, populations, years and definitions, so this is an indirect comparison; the bars show where pathways carry the most load, not how one outcome compares with another.
Limitation. Each value reflects its own setting and denominator; several are from single centers and one is self-reported.
Figure data (5 rows)
| Measure | Value | Population, setting and year as reported | Source |
|---|---|---|---|
| Diagnostic delay of one year or more | 47.3% | 150 adults at a Brazilian public tertiary center, evaluated 2024 to 2025 | [1] |
| Required mechanical ventilation during intensive care stay | 45% | 24 patients with 60 intensive care admissions over six years at a Saudi tertiary center | [14] |
| Received intensive treatment within one year of diagnosis | 19.9% | 261 patients aged 0 to 17 with juvenile generalized disease, Japanese claims database, 2008 to 2024 | [11] |
| Responding to intravenous immunoglobulin at day 180 | 46.7% | 1,041 patients with generalized disease at 316 Japanese facilities, 2011 to 2016 | [9] |
| Employment restrictions among seronegative patients | 64.4% | 237 seronegative patients in a questionnaire-based survey | [13] |

Continuum of care
Preventing crises and managing transitions
Crisis care is a major driver of intensive resource use. At a Saudi tertiary center, 24 patients accounted for 60 intensive care admissions over six years.[14] Myasthenic crisis was the most common reason for admission (63.3%), and 45% of patients required mechanical ventilation during their stay.[14] Complications were reported in 18.3%, and mortality was 5% of all admissions.[14] Repeat admissions among a small group of patients suggest that crisis prevention should focus on known high-risk individuals.
Exacerbations also multiply costs. In the U.S. database study, mean monthly healthcare costs reached $17,330 among patients with an exacerbation or crisis.[15] Patients with generalized disease had 4.36 times more inpatient admissions and 2.26 times more outpatient visits than matched patients without the disease.[15] Comorbid psychiatric conditions raised costs by 34%, which points to integrated behavioral health as part of the continuum.[15]
Transitions in life stage carry specific risks. A Swedish national register study of 112 women with 176 pregnancies found that pregnancy itself was not associated with more admissions for myasthenia gravis.[12] The first three months postpartum, however, carried a higher risk of prolonged admissions, with a hazard ratio of 5.02.[12] The authors highlighted the importance of close monitoring after delivery.[12] Medications were initiated or escalated postpartum in 10 pregnancies and reduced in none.[12] That finding makes the handoff between obstetric and neuromuscular teams a clear control point.
Children and adolescents need their own pathway. In a Japanese claims study of 261 patients with juvenile generalized disease, 19.9% received intensive treatments within a year of diagnosis.[11] Adolescents received intensive treatment more often than younger children (25.7% compared with 13.6%) and had higher intensive care rates (8.8% compared with 0.8%).[11] Steroid-sparing immunosuppression was used in only about one third, at 34.1%.[11] Transition planning from pediatric to adult neuromuscular care should account for this higher-risk adolescent group.
Each of these transitions, from outpatient to crisis, from pregnancy to postpartum and from childhood to adolescence, is a predictable moment of risk. Systems that flag them in advance can schedule closer follow-up rather than waiting for an emergency presentation.[11][12][14] A shared crisis plan, known to the patient, the emergency department and the neuromuscular team, can also shorten the time to rescue treatment when a crisis does occur. Reviewing every crisis admission for missed warning signs turns each event into a learning opportunity.
Figure 3
Why the pathway breaks
People
- Few neuromuscular specialists
- Front-line clinicians unfamiliar with fatigue without obvious weakness
- Limited behavioral health and caregiver support
Process
- No fast route from eye, primary and emergency care to neuromuscular review
- Immunosuppressants started before diagnosis is confirmed
- No planned follow-up after delivery or during adolescence
Technology
- Patient-reported outcomes not collected between visits
- Remote monitoring not staffed for high-risk patients
- False positive or test-only diagnoses
Environment
- Distance to specialty centers
- Resource-limited public systems
- Infusion chair and plasma exchange capacity limits
Policy
- Prior authorization delays for specialty therapies
- High out-of-pocket and employment impacts
- Inconsistent coverage for newer outpatient therapies
Measurement
- Diagnostic delay not tracked
- Admissions and intubations not stratified by race, ethnicity or sex
- Costs not linked to exacerbation prevention
Unranked qualitative cause-and-effect diagram for the outcome in the box: People with myasthenia gravis experience long diagnostic delays, avoidable crises and high hospital use Causes are assembled from the cited literature [2], [3], [4], [5], [6], [7], [8], [9], [12], [15]; categories are not weighted and their order carries no meaning.
Data note. Qualitative; no frequencies are implied.
Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.
Figure data (6 rows)
| Category | Causes drawn from the cited literature |
|---|---|
| People | Few neuromuscular specialists; Front-line clinicians unfamiliar with fatigue without obvious weakness; Limited behavioral health and caregiver support |
| Process | No fast route from eye, primary and emergency care to neuromuscular review; Immunosuppressants started before diagnosis is confirmed; No planned follow-up after delivery or during adolescence |
| Technology | Patient-reported outcomes not collected between visits; Remote monitoring not staffed for high-risk patients; False positive or test-only diagnoses |
| Environment | Distance to specialty centers; Resource-limited public systems; Infusion chair and plasma exchange capacity limits |
| Policy | Prior authorization delays for specialty therapies; High out-of-pocket and employment impacts; Inconsistent coverage for newer outpatient therapies |
| Measurement | Diagnostic delay not tracked; Admissions and intubations not stratified by race, ethnicity or sex; Costs not linked to exacerbation prevention |
Access
Infusion capacity, specialty therapies and remote monitoring
Infusion services are a core part of myasthenia gravis care. A Japanese post-marketing study followed 1,041 patients with generalized disease who received intravenous immunoglobulin at 316 facilities.[9] The median time to retreatment was 386 days overall but only 175 days among 410 patients who needed a second dose.[9] The responder rate was 65.7% at day 14 and 46.7% at day 180.[9] Those figures help planners anticipate recurring infusion demand for a subset of patients.
Newer outpatient therapies may shift demand from inpatient beds to infusion chairs and specialty pharmacy. In a retrospective study of 67 patients, 12 switched from intravenous immunoglobulin to efgartigimod, and hospitalizations decreased significantly after the switch.[10] Quality of life scores also improved, with responses favoring support for family roles, work participation and social activities.[10] The sample was small and observational, so the result is a planning signal rather than a firm estimate.[10]
Trial data point in a similar direction. In a post hoc analysis of 153 patients in a randomized trial, nipocalimab reduced all-cause and disease-related hospital days per 100 patient-years by 60% and 68% compared with placebo.[8] Estimated cost offsets were $10,860 to $13,253 per patient per year.[8] Worsening daily activity scores and higher baseline respiratory scores independently predicted high-cost events.[8] These results suggest that payers and health systems can identify patients most likely to need intensive support.
Remote monitoring offers a way to see worsening between visits. In a randomized 12-week study, 30 patients used a telemedical platform with patient-reported outcomes, sensor data and messaging.[7] Patients who were later hospitalized or had exacerbations showed larger fluctuations in daily activity scores, with a mean range of 5.8 compared with 2.6 points.[7] That subgroup had more steroid dose adjustments (40% compared with 0%) and more frequent telemedical check-up interventions (93.3% compared with 60%).[7] The authors concluded that such platforms might detect early signs of worsening.[7]
Access, in this context, means having the right modality available when a patient’s condition changes. Infusion chairs, plasma exchange, specialty pharmacy authorization and remote check-ins must all be scheduled with enough slack to respond quickly.[7][8][9] Capacity plans built only on average demand will fail at the moment a patient worsens. Home infusion and community infusion sites can extend reach, but they need clear protocols for escalation back to hospital care.
Executive guidance · System route
Build one visible operating route for Myasthenia Gravis Awareness Month.
Use this route as a discussion framework. Replace each stage with the organization’s approved process, qualified roles, current service capacity, and applicable requirements. Do not infer a clinical protocol from the observance title.
The route at a glance
- Listen
- Clarify entry
- Coordinate the partner route
- Protect transitions
- Verify and learn
Reliability rule: Every stage needs a named owner, an observable status, an approved escalation path, and a defined signal that shows whether responsibility moved or remained unresolved.
Listen
Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions.
Clarify entry
Publish a plain-language first step and identify who receives requests through each approved channel.
Coordinate the partner route
Align internal teams and external partners around one current message, real entry point, receiving owner, escalation path, and follow-through signal.
Protect transitions
Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations.
Verify and learn
Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals.
Figure 2
The system route as one flow
The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.
Data note. Shows sequence and handoffs only; it carries no counts or rates.
Limitation. Local processes may add, merge or reorder stages under organizational policy.
Figure data (5 rows)
| Stage | What the stage requires |
|---|---|
| Listen | Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions. |
| Clarify entry | Publish a plain-language first step and identify who receives requests through each approved channel. |
| Coordinate the partner route | Align internal teams and external partners around one current message, real entry point, receiving owner, escalation path, and follow-through signal. |
| Protect transitions | Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations. |
| Verify and learn | Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals. |
Equity and trust
Disease burden is not shared equally
Disease burden varies by race and ethnicity. A study using a national patient registry of 3,744 adults and national inpatient data found that African American and Hispanic patients more often had early-onset disease and generalized symptoms.[5] African American and Indigenous patients had higher daily activity and quality of life burden scores at enrollment.[5] In 62,055 hospitalizations for worsening disease, African American and Hispanic patients had 1.4 and 1.7 times greater odds of intubation than White patients.[5]
Hospital costs followed the same pattern. The average cost of hospitalization was 150% higher for African American patients than for White patients.[5] Anxiety or depression was 300% more common among hospitalized registry patients.[5] The authors concluded that African American, Hispanic and Indigenous patients faced greater burden in daily life, quality of life, inpatient outcomes and costs.[5] These findings call for stratified reporting of admissions, intubations and costs.
Sex differences matter as well. In a Belgian reference center cohort of 163 patients, women experienced diagnostic delays of more than one year more often than men.[4] Women also had higher severity scores at maximum disease severity, reported more limitations, and required more treatments.[4] Some differences were independent of the younger age at onset in women.[4] The authors recommended that follow-up and treatment strategies take these differences into account.[4]
Public health systems face particular constraints. The Brazilian cohort was female-predominant (65.3%), and refractory disease occurred in 14% of patients.[1] Treatment-related adverse events were documented in 47.5%, most commonly hyperglycemia.[1] The authors highlighted the need for steroid-sparing strategies and improved access to comprehensive care in resource-limited settings.[1] In many U.S. communities, insurance and distance create similar barriers to specialized care. Telehealth follow-up, travel support and coordinated scheduling of tests and visits can reduce the number of trips a patient must make.
Trust grows when patients see that their experience is measured and acted on. Seronegative patients reported more employment restrictions and worse quality of life, a reminder that groups with less certain diagnoses can feel overlooked.[13] Equity work in myasthenia gravis can therefore track diagnostic delay, crisis rates and access to specialty therapies by race, ethnicity, sex and antibody status. Reviewing those results with patient advisers helps leaders understand reasons that data alone may not reveal.

Human infrastructure
Neuromuscular expertise as a shared resource
Neuromuscular specialists are scarce, and the evidence shows why their judgment matters. In the specialized clinic study, the clinical picture was the cornerstone of diagnosis, and in 30% of the mimic group no further studies were needed.[2] Up to 19% of mimic patients showed abnormalities on single fiber electromyography, so relying on that test alone could produce errors.[2] Expert review can therefore prevent both missed diagnoses and unnecessary treatment.
Front-line clinicians need support to recognize atypical presentations. In the Lambert-Eaton study, reduced or absent tendon reflexes were found in 91.7% of patients and reduced nerve response amplitudes in 91.7%.[3] Those findings appeared despite normal strength testing in most patients.[3] Education for primary care, ophthalmology and emergency teams about fatigue without obvious weakness may shorten the path to specialist review.
Remote models can stretch specialist time. In the telemedical study, physicians performed check-ups through a web-based platform and adjusted treatment as needed.[7] High-risk patients sent more messages and needed more interventions, which suggests that remote programs need staffing matched to the patients most likely to worsen.[7] Nurses, pharmacists and care coordinators can triage messages so that neurologists focus on clinical decisions. Clear escalation rules, shared protocols and protected time make that division of labor safe. Without them, remote programs can add unplanned work to already stretched specialist schedules.
Infusion and pharmacy teams are part of the same workforce. Intravenous immunoglobulin was used across 316 facilities in the Japanese surveillance study, which shows how widely infusion capability is distributed.[9] In the Japanese juvenile cohort, intravenous immunoglobulin was the most common intensive treatment at 13.4%, followed by steroid pulse therapy at 10.3% and plasma exchange at 3.8%.[11] Planning for nursing, apheresis and pharmacy staffing should reflect this mix of demand. Cross-training infusion nurses on neuromuscular protocols and keeping a small reserve of apheresis capacity can prevent delays during surges in crisis admissions.
Behavioral health and social work belong in the team. Psychiatric comorbidity raised monthly costs by 34% in the U.S. database study, and caregivers reported strong financial and sleep impacts.[6][15] Support for families, employment and financial navigation addresses domains that patients and caregivers rated as most affected.[6] Workforce plans that include these roles treat the condition as patients experience it, rather than only as a series of clinical encounters.
Executive guidance · Operating dashboard
Use a small dashboard to expose friction and ownership.
Do not publish a number until the organization defines its numerator, denominator where relevant, owner, source system, exclusions, review cadence, and limits. The candidates below are management prompts, not benchmarks or reported results.
Four operating signals
Each signal pairs an executive question with one candidate local measure, set out below.
Executive guidance · Signal
Entry-point clarity
Can people and staff identify the approved first step without searching across conflicting instructions?
- Candidate local measure
- Locally defined contact, routing, and repeat-contact signals by channel and service.
Executive guidance · Signal
Ownership reliability
Does a specific team accept each request and make its status visible?
- Candidate local measure
- Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
Executive guidance · Signal
Partner-route reliability
Do participating teams share one current route and understand who owns each dependency?
- Candidate local measure
- Locally defined conflicting instructions, unaccepted handoffs, unresolved dependencies, repeat contacts, and partner feedback.
Executive guidance · Signal
Improvement closure
Does the organization correct recurring friction and report what changed?
- Candidate local measure
- Selected barriers, assigned actions, completion status, and post-change review.
Figure 4
The operating system behind the dashboard
The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.
Data note. Structural diagram; no measured values.
Limitation. Owners are candidates to be confirmed locally.
Figure data (4 rows)
| Operating signal | Candidate owner |
|---|---|
| Entry-point clarity | Executive sponsor and operational lead |
| Ownership reliability | Operational owner and participating teams |
| Partner-route reliability | Sending and receiving owners |
| Improvement closure | Improvement owner and executive sponsor |
Executive guidance · Handoff workflow
Close the loop across teams, settings, and partners.
A handoff is reliable only when the sending party knows who is expected to receive the work, the receiving party acknowledges responsibility, and any unresolved exception remains visible. Local policy and qualified judgment control the actual process.
How responsibility moves
Lane A
From message to accepted ownership
- Confirm the approved message and intended audience.
- Publish the actual entry point and receiving role.
- Acknowledge receipt using the locally approved method.
- Escalate when ownership or response remains unclear.
Lane B
From accepted ownership to verified follow-through
- Record the next accountable owner and visible status.
- Name the sending and receiving owners, shared information, current status, and unresolved dependency.
- Keep unresolved work visible across boundaries.
- Confirm closure or document the continuing exception.
Executive guidance · Executive scorecard
Give leaders one view of route reliability and improvement.
The scorecard keeps review focused on decisions. Leaders should set definitions locally, examine variation without overclaiming cause, and pair quantitative signals with the experience of people who use and operate the route.
Who reviews what
- Executive sponsor and operational lead
- Operational owner and participating teams
- Sending and receiving owners
- Improvement owner and executive sponsor
Candidate owners named in the scorecard, confirmed locally.
| Operating signal | Executive question | Candidate owner | Suggested review point |
|---|---|---|---|
| Entry-point clarity | Can people and staff identify the approved first step without searching across conflicting instructions? | Executive sponsor and operational lead | At campaign launch and close |
| Ownership reliability | Does a specific team accept each request and make its status visible? | Operational owner and participating teams | At a locally defined cadence |
| Partner-route reliability | Do participating teams share one current route and understand who owns each dependency? | Sending and receiving owners | At a locally defined cadence |
| Improvement closure | Does the organization correct recurring friction and report what changed? | Improvement owner and executive sponsor | Until action is verified |
Figure 5
Control points for a reliable myasthenia gravis pathway
| Control point | Risk if missing | Owner | Evidence of control |
|---|---|---|---|
| Rapid neuromuscular referral route for suspected cases | Long diagnostic delays and late recognition of worsening | Chief medical officer with neurology division chief | Median days from first suspicion to neuromuscular evaluation |
| Expert confirmation before long-term immunosuppression | Mimic conditions treated with unnecessary immunosuppressants | Neuromuscular program director | Share of new diagnoses confirmed by specialist review |
| High-risk patient registry with crisis plans | Repeat crises and intensive care admissions in a small group | Neurology and critical care leads | Crisis admissions per registered patient per year |
| Postpartum and adolescent follow-up protocols | Prolonged admissions after delivery and intensive treatment in adolescents | Women’s health and pediatric neurology leads | Share of postpartum and adolescent patients with scheduled neuromuscular follow-up |
| Infusion, plasma exchange and specialty pharmacy capacity plan | Delayed treatment when patients worsen | Infusion services director and specialty pharmacy manager | Days from order to treatment for rescue and maintenance therapies |
| Remote patient-reported outcome monitoring | Worsening missed between visits | Digital health program manager | Share of enrolled patients with weekly scores reviewed and acted on |
| Stratified outcome reporting | Higher burden among minoritized patients and women stays hidden | Chief health equity officer with board quality committee | Delay, intubation and cost reported by race, ethnicity and sex |
Control points derived from the cited evidence [1], [2], [4], [5], [7], [8], [9], [11], [12], [14] and this brief’s executive guidance.
Data note. Each row is a control to verify, not a measured result.
Limitation. Owners and evidence of control must follow local policy and applicable requirements.
Public communication
Messages that shorten the path to diagnosis
Public communication during Myasthenia Gravis Awareness Month can focus on recognition and routes to care. The Brazilian and Belgian studies both found frequent delays of a year or more.[1][4] Messages that describe fluctuating weakness, eyelid drooping, double vision and swallowing difficulty can help patients and clinicians act sooner. They work best when they also name where to seek evaluation and how quickly the organization can see a new patient. Awareness without a clear route can simply add to the queue.
Communication also needs to address the burden that patients describe. Patients in the U.S. survey rated occupational and planning impacts highest, while caregivers emphasized financial strain and sleep.[6] Messages that acknowledge work, family and financial effects are more likely to resonate than those that focus on symptoms alone.[6] Employers and community partners can be part of that audience. Practical information about flexible work, rest breaks and transportation can reduce the occupational and financial strain that patients described.[6] Caregivers deserve their own messages, since they reported impacts on sleep, finances and safety.[6]
Clinician-facing messages are equally important. The specialized clinic study showed that a positive antibody result was sometimes a false positive and that some patients received immunosuppressants before the diagnosis was confirmed.[2] Short, practical guidance for referring clinicians on when to refer and what not to start can reduce harm and wasted resources.[2] Communication with obstetric teams about the postpartum period also matters, given the higher risk of prolonged admissions in the first months after delivery.[12]
Communication should be equitable and measured. Given the higher burden among African American, Hispanic and Indigenous patients, outreach can be designed with community partners and patient organizations that serve those groups.[5] Health systems can track whether outreach is followed by more timely neuromuscular referrals, fewer emergency presentations and better patient-reported outcomes. Materials should be available in the languages patients speak and tested with patient advisers before release. Patient organizations can help reach people who have struggled to obtain a diagnosis, including those with seronegative disease.[13]
Finally, leaders can share results openly. Reporting diagnostic delay, crisis admissions and patient-reported outcomes to staff, patients and boards turns a month of awareness into a durable accountability cycle. Patient-reported outcome data from remote platforms can feed that reporting directly.[7]

Executive guidance · 90-day plan
Turn the observance into one sustained operating change.
The time boxes below are a management framework, not a clinical timeline. Adjust them to risk, scope, governance, resources, stakeholder participation, and applicable review requirements.
Ninety days, three moves
- Days 1–30See the current route
- Days 31–60Build the reliable path
- Days 61–90Make the change visible
Days 1–30 · Listen and map
See the current route
- Name an executive sponsor and an operational owner.
- Listen to people using the route and representative frontline teams.
- Map how Myasthenia Gravis Awareness Month communications connect to real entry points, owners, transitions, and escalation.
- Select one recurring barrier that the organization can responsibly address.
Days 31–60 · Design and test
Build the reliable path
- Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
- Validate the design with every sending and receiving team involved.
- Test one internal or partner handoff and correct a verified communication, dependency, or ownership gap.
- Test the route in more than one representative setting or operating period where practical.
Days 61–90 · Implement and verify
Make the change visible
- Launch the redesigned route with a small set of locally defined measures.
- Review unresolved work and recurring friction using a learning approach.
- Correct implementation barriers and record who owns each remaining dependency.
- Report what changed, what evidence was reviewed, and what still requires live oversight.
Figure 6
The 90-day plan on one timeline
The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.
Data note. Time boxes are a management framework, not a clinical timeline.
Limitation. Durations are uniform 30-day windows; real tasks may span windows.
Figure data (12 rows)
| Window | Action |
|---|---|
| Days 1–30 · Listen and map | Name an executive sponsor and an operational owner. |
| Days 1–30 · Listen and map | Listen to people using the route and representative frontline teams. |
| Days 1–30 · Listen and map | Map how Myasthenia Gravis Awareness Month communications connect to real entry points, owners, transitions, and escalation. |
| Days 1–30 · Listen and map | Select one recurring barrier that the organization can responsibly address. |
| Days 31–60 · Design and test | Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal. |
| Days 31–60 · Design and test | Validate the design with every sending and receiving team involved. |
| Days 31–60 · Design and test | Test one internal or partner handoff and correct a verified communication, dependency, or ownership gap. |
| Days 31–60 · Design and test | Test the route in more than one representative setting or operating period where practical. |
| Days 61–90 · Implement and verify | Launch the redesigned route with a small set of locally defined measures. |
| Days 61–90 · Implement and verify | Review unresolved work and recurring friction using a learning approach. |
| Days 61–90 · Implement and verify | Correct implementation barriers and record who owns each remaining dependency. |
| Days 61–90 · Implement and verify | Report what changed, what evidence was reviewed, and what still requires live oversight. |
Executive guidance · Leadership close
Make Myasthenia Gravis Awareness Month a starting point, not an endpoint.
Recognition matters. It becomes durable when leaders also listen, clarify the route, support the people operating it, close an identified gap, and report the result without claiming more than the evidence supports.
Leadership commitment
Make ownership visible, test the route, and report what improved.
Executive action kit · Month observance
Turn Myasthenia Gravis Awareness Month into accountable action.
A practical executive framework for access, ownership, handoffs, measurement, and improvement.
Leadership focus
Use this observance to examine trustworthy information, prevention access, and community connection. Select one verified barrier, assign an accountable owner, and carry the improvement beyond the campaign window.
Workforce lens
Ask whether staffing, role clarity, training, tools, workload, and escalation support the people operating the information, access, coordination, and follow-through pathway.
Patient and community lens
Make the approved first step clear. Test whether a person can move from information to an acknowledged next action without navigating conflicting instructions.
Equity and access lens
Review language, disability, transportation, digital access, geography, trust, and other barriers using protected feedback and locally appropriate data.
Five-minute briefing
Inspect the operating sequence
Listen with people using the pathway, frontline teams, operational leaders, and community partners. Find one a message, request, referral, or handoff that does not reach an accountable owner, then test the locally approved route from entry through acknowledged follow-through.
- Listen
- Clarify entry
- Coordinate the partner route
- Protect transitions
- Verify and learn
Leadership actions for this week
- Name an executive sponsor and frontline operating owner.
- Ask people using and operating the pathway where ownership becomes unclear.
- Test one representative route from first question to acknowledged next step.
- Select one barrier that can be corrected without overstating the evidence.
- Set a review date and define how completion will be verified.
Candidate measures
Define every numerator, denominator where relevant, owner, data source, exclusions, cadence, and limitation locally. These are management prompts, not external benchmarks.
- Locally defined contact, routing, and repeat-contact signals by channel and service.
- Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
- Locally defined conflicting instructions, unaccepted handoffs, unresolved dependencies, repeat contacts, and partner feedback.
Department readiness checklist
- The public and staff entry points match the actual approved process.
- A specific role accepts each request, referral, or escalation.
- Handoffs include acknowledgment and a visible unresolved state.
- Language, disability, digital, transportation, and trust barriers receive explicit review.
- Communications do not introduce unsupported themes, statistics, or clinical advice.
- A named leader will review what changed after the observance.
Intended audiences
- Executive and Operational Leaders
- Public Health and Community Partners
Staff communication template
During Myasthenia Gravis Awareness Month, our organization will connect awareness with a practical review of the information, access, coordination, and follow-through pathway. Use approved information, identify the correct entry point, confirm ownership when work moves, protect privacy, and escalate unresolved barriers through local channels.
Community communication template
Myasthenia Gravis Awareness Month is an opportunity to share trustworthy information and make the next step easier to find. Use our approved channels for information and support. If a request changes hands, our goal is to keep ownership and follow-through visible.
Measurement worksheet
- Signal
- What observable condition will show whether the route works?
- Definition
- What is included, excluded, and counted?
- Owner
- Who reviews the signal and acts on exceptions?
- Cadence
- When will leaders review it?
- Equity check
- Which differences require protected, locally appropriate review?
- Closure
- What evidence will confirm the improvement was completed?
- Editorial review
- Completed
- Source records
- 2 listed under Authoritative resources
- Review standard
- Sourced facts remain separated from original executive guidance
- Clinical boundary
- No new statistical or clinical claim was added by this action kit
Sources and content boundary
Authoritative resources
Use note: All operating models, measures, scorecard questions, and action steps are original executive guidance. This article supports leadership planning and education. It does not replace clinical judgment, emergency procedures, legal advice, professional standards, organizational policy, or applicable federal, state, and local requirements.
Peer-reviewed references
References
Fifteen peer-reviewed sources, newest first. Each was individually verified through authenticated academic research databases. Bracketed numbers in the text link here; the original executive guidance on this page carries no citations because it is guidance, not a sourced claim. Sources last checked in those databases on .
- 1.Figueiredo DS, Martinez ARM, Nucci A, França Junior MC. Myasthenia gravis: Diagnostic journey and therapeutic outcomes in patients followed at a Brazilian public tertiary center — A retrospective cohort study. PLOS ONE. 2026;21(7):1-15. https://doi.org/10.1371/journal.pone.0353883
- 2.Vesperinas A, Rocaspana-Codana J, Reyes-Leiva D, Caballero-Ávila M, Carbayo Á, Collet-Vidiella R, et al. Challenges in myasthenia gravis diagnosis: an analysis of the diagnostic process of myasthenia gravis in a specialized clinic. Neuromuscular Disorders. 2026;59. https://doi.org/10.1016/j.nmd.2025.106284
- 3.Handa H, Uzawa A, Shibuya K, Kojima Y, Suichi T, Yasuda M, et al. Diagnosis of Lambert-Eaton myasthenic syndrome: Muscle fatigue with normal manual muscle testing, areflexia, and electrodiagnostic findings. Journal of Neuroimmunology. 2026;417:578917. https://doi.org/10.1016/j.jneuroim.2026.578917
- 4.Alonso-Jiménez A, De Ridder W, Van Schil P, Baets J, Mercelis R. Gender differences in Myasthenia Gravis in a neuromuscular reference center in Belgium. Acta Neurologica Belgica. 2026;126(3):957-965. https://doi.org/10.1007/s13760-025-02977-8
- 5.McLaren N, Gutierrez AZ, Joo D, Roy B, Park M, Nowak RJ. Variations in clinical features and disease burden of myasthenia gravis between racial and ethnic groups: A retrospective cohort study of two national databases. Journal of the Neurological Sciences. 2026;481. https://doi.org/10.1016/j.jns.2026.125740
- 6.Narayanaswami P, Sullivan J, Thiele C, Ramirez C, dosReis S, Foss A, et al. Characterizing and quantifying disease impacts of generalized myasthenia gravis (gMG) in the United States: insights from patient and caregiver interviews and surveys. Journal of Patient-Reported Outcomes. 2026;10(1). https://doi.org/10.1186/s41687-026-01124-y
- 7.Stein M, Mönch M, Herdick M, Stascheit F, Hoffmann S, Preßler H, et al. Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability. Annals of Clinical and Translational Neurology. 2026;13(6):1106-1117. https://doi.org/10.1002/acn3.70293
- 8.Vissing J, Coteur G, Turkoz I, Gandhi K. Hospital resource utilization in patients with generalized myasthenia gravis treated with nipocalimab: results from the VIVACITY-MG3 study. Journal of Medical Economics. 2026;29(1):1964-1973. https://doi.org/10.1080/13696998.2026.2700423
- 9.Suzuki S, Iida M, Wakahara T, Shiko Y, Murai H. Long-term effectiveness, safety, and cost-effectiveness of intravenous immunoglobulin for generalized myasthenia gravis in an era of molecular targeted drugs: Insights from Japanese post-marketing surveillance. Journal of Autoimmunity. 2026;162. https://doi.org/10.1016/j.jaut.2026.103588
- 10.Yasaka A, Watanabe G, Saito M, Tamagake A, Sasaki C, Akao G, et al. Clinical and quality-of-life outcomes associated with efgartigimod in patients with generalized myasthenia gravis transitioning from intravenous immunoglobulin. Clinical Neurology and Neurosurgery. 2026;265. https://doi.org/10.1016/j.clineuro.2026.109389
- 11.Ishigaki K, Horio H, Kitamura T, Saga Y. Treatment patterns, intensive treatment, and hospitalization-related burden of juvenile generalized myasthenia gravis in Japan: a retrospective cohort study using a hospital-based claims database. Frontiers in Neurology. 2026;17:1877931. https://doi.org/10.3389/fneur.2026.1877931
- 12.O’Connor L, Gabrysch K, Wikström AK, Rostedt Punga A. Risk of Myasthenia Gravis Exacerbation During Pregnancy and Postpartum: A Nationwide Cohort Study. Neurology. 2026;106(12):e218082. https://doi.org/10.1212/wnl.0000000000218082
- 13.Lehnerer S, Stegherr R, Grittner U, Stein M, Gerischer L, Stascheit F, et al. The burden of disease in seronegative myasthenia gravis: a patient-centered perspective. Frontiers in Immunology. 2025;16:1555075. https://doi.org/10.3389/fimmu.2025.1555075
- 14.Attar A, Alshaikh H, Alharbi G, Aletani T, Alghamdi S, Alzahrani S, et al. Outcomes of myasthenia gravis patients admitted to the Intensive Care Unit: Experience from a tertiary care center in Saudi Arabia. PLOS ONE. 2025;20(7):e0328648. https://doi.org/10.1371/journal.pone.0328648
- 15.Zhdanava M, Pesa J, Boonmak P, Cai Q, Pilon D, Choudhry Z, et al. Economic burden of generalized myasthenia gravis (MG) in the United States and the impact of common comorbidities and acute MG-events. Current Medical Research and Opinion. 2024;40(7):1145-1153. https://doi.org/10.1080/03007995.2024.2353381
Claim-to-source matrix
What each source supports
Every sourced claim in the new sections maps to the references that support it, the section where it is used, and the limitation a reader should keep in mind. Original executive guidance carries no sources because it is guidance, not a finding.
| Claim group | Sources | Years | Used in | Limitation |
|---|---|---|---|---|
| Diagnostic delay and crisis frequency in a public tertiary center | [1] | 2026 | Current evidence | Single-center retrospective Brazilian cohort; some data from questionnaires. |
| Misdiagnosis and mimics among referred patients | [2] | 2026 | Current evidence | Single specialized clinic; referral population may not reflect primary care. |
| Diagnostic delay in Lambert-Eaton myasthenic syndrome | [3] | 2026 | Current evidence | Small retrospective sample of 12 and 20 patients. |
| Burden and delay in seronegative myasthenia gravis | [13] | 2025 | Current evidence | Self-reported survey data; possible selection bias. |
| Patient and caregiver life impacts | [6] | 2026 | Current evidence | Survey ratings of relevance from an independent sample; not a prevalence estimate. |
| Intensive care admissions for myasthenic crisis | [14] | 2025 | Continuum of care | 24 patients at one Saudi tertiary center. |
| Incremental costs and utilization of generalized myasthenia gravis | [15] | 2024 | Continuum of care | U.S. claims database 2017 to 2021; costs in 2021 dollars. |
| Postpartum risk of prolonged admissions | [12] | 2026 | Continuum of care | Swedish register; milder exacerbations may be underestimated. |
| Intensive treatment in juvenile generalized disease | [11] | 2026 | Continuum of care | Hospital-based claims database; one-year follow-up. |
| Retreatment intervals and response to intravenous immunoglobulin | [9] | 2026 | Access | Post-marketing surveillance 2011 to 2016 in Japan. |
| Outpatient therapy switch and hospitalizations | [10] | 2026 | Access | Small observational study with 12 switched patients. |
| Hospital resource use with newer targeted therapy | [8] | 2026 | Access | Post hoc trial analysis; short duration; modeled U.S. costs. |
| Remote monitoring of symptom variability | [7] | 2026 | Access | 12-week randomized study of 45 patients; exploratory subgroup comparisons. |
| Racial and ethnic differences in burden, intubation and cost | [5] | 2026 | Equity and trust | Self-reported registry and administrative inpatient data. |
| Sex differences in delay and severity | [4] | 2026 | Equity and trust | Single Belgian reference center cohort of 163 patients. |

About the author
Greg Wahlstrom
MBAHCM
President and Chief Executive Officer, The Healthcare Executive
View Greg’s profile©2014 – 2026 The Healthcare Executive. All rights reserved.

